Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Overview
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Asahi Kasei Pharma Corp
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Bayer AG
Beijing Hanmi Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Emmaus Life Sciences Inc
Evommune Inc
Fresh Tracks Therapeutics Inc
Gilead Sciences Inc
Kurome Therapeutics Inc
Kymera Therapeutics Inc
Nyrada Inc
Pfizer Inc
Rigel Pharmaceuticals Inc
TG Therapeutics Inc
Xi’An Yufan Biotechnology Co Ltd
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Drug Profiles
AK-179 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AS-2444697 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AZD-6793 - Drug Profile
Product Description
Mechanism Of Action
BAY-1830839 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-986126 - Drug Profile
Product Description
Mechanism Of Action
History of Events
emavusertib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
EVO-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
FRTX-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GS-5718 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IRAK4 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KM-10544 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KT-413 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KT-474 - Drug Profile
Product Description
Mechanism Of Action
History of Events
R-289 - Drug Profile
Product Description
Mechanism Of Action
History of Events
R-835 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit IRAK4 for Rheumatoid Arthritis and Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecules 1 to Inhibit IRAK4 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit IRAK1 and IRAK4 for Acute Myelocytic Leukemia and Myelodysplastic Syndrome - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit IRAK4 for Autoimmune Disorders, Cardiovascular Disease, Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit IRAK4 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
TQH-3821 - Drug Profile
Product Description
Mechanism Of Action
zabedosertib - Drug Profile
Product Description
Mechanism Of Action
History of Events
zimlovisertib - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZYF-0116 - Drug Profile
Product Description
Mechanism Of Action
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Dormant Products
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Discontinued Products
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022